

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

				······································	
APPLICATION NO.	FILING DAT	TE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/601,005	03/01/1996		KJELL BACKSTROM	06275/034001	2853
FISH & RICHARDSON PC 225 FRANKLIN ST BOSTON, MA 02110				EXAMINER	
				CHOI, FRANK I	
				ART UNIT	PAPER NUMBER
				1616	
				DATE MAILED: 11/03/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	08/601,005	BACKSTROM ET AL.				
Office Action Summary	Examiner	Art Unit				
	Frank I Choi	1616				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a re If NO period for reply is specified above, the maximum statutory perio - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mai earned patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a eply within the statutory minimum of the d will apply and will expire SIX (6) MC	a reply be timely filed nirty (30) days will be considered timely. NTHS from the mailing date of this communication.				
Status						
1) Responsive to communication(s) filed on 23	July 2004					
2a) This action is FINAL . 2b) ⊠ Th	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) <u>46,54-77 and 80-107</u> is/are pending 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) <u>46,54-58,61-77,80,82,83 and 96-10</u> 7) Claim(s) <u>59,60,81,84-95 and 102-107</u> is/are callowed.	awn from consideration. 1 is/are rejected. bbjected to.					
Application Papers						
9)⊠ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) acc	cepted or b) objected to	by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119	Administration the attached	7 Office Action of form PTO-152.				
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	ts have been received. ts have been received in A rity documents have been u (PCT Rule 17.2(a)).	pplication No received in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 12/24/2002.	Paper No(s)	ummary (PTO-413) /Mail Date formal Patent Application (PTO-152) 				

Application/Control Number: 08/601,005

Art Unit: 1616

DETAILED ACTION

Priority

Please amend first sentence of Specification after title to indicate the following: "This application is a 371 of PCT/SE95/01542 filed on December 12, 1995.".

Claim Objections

Claim 74,75 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claims 74,75 do not indicate that the end result is that the medicament and the surfactant are suspended in the propellant as a finely divided powder, as such, it appears that the end product of the process is greater in scope than the claimed aerosol formulation in claim 46.

Claims 59,60,81,84-95,102-107 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims or if a terminal disclaimer is filed with respect to US Pat. 6,524,557.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground

Application/Control Number: 08/601,005

Art Unit: 1616

provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 46, 54-58,61-77,80,82-83,96-101 rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1,10-41,48-62.74-105,114-127 of U.S. Patent No. 6,524,557. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the US Patent are directed to pharmaceutical aerosol formulations, methods of using and methods of preparing the same containing HFA propellant, a polypeptide medication which is inhaled having a micron size of less than 10 microns and an alkyl saccharide surfactant where the medication is dispersed in the propellant and the surfactant is dispersed in the propellant as solid particles. The claimed invention is directed to a pharmaceutical aerosol formulation, methods of using and methods of preparing the same containing HFA propellant, a "medicament for inhalation" and an alkyl saccharide surfactant, where the medicament and surfactant are dispersed in the propellant as a finely divided powder. Since the polypeptide is a medicament and is inhaled one of ordinary skill in the art would recognize that the polypeptide is a "medicament for inhalation." Therefore, the claimed invention, as a whole, would have been an obvious modification of said claims of US Pat. 6,524,557 to one of ordinary skill in the art at the time the invention was made, because every element of the invention has been collectively taught by the combined teachings of the said claims of said US. Patent.

Art Unit: 1616

Conclusion

A facsimile center has been established in Technology Center 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier number for accessing the facsimile machine is (703) 872-9306.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Choi whose telephone number is (571)272-0610. Examiner maintains a flexible schedule. However, Examiner may generally be reached Monday-Friday, 8:00 am - 5:30 pm (EST), except the first Friday of the each biweek which is Examiner's normally scheduled day off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Mr. Gary Kunz, can be reached at 571-272-0887. Additionally, Technology Center 1600's Receptionist and Customer Service can be reached at (571) 272-1600. FIC

October 30, 2004

SABIHA QÁZÍ, PH.O PRIMARY EXAMINES

503